NRIX Nasdaq Pharmaceutical Preparations Financials FY2019βFY2025
Nurix Therapeutics, Inc. had $84.0M of revenue in fiscal 2025, up 54.0% on the year before. Over five years, revenue changed +36.3% a year on average.
Last close Β· Oct 23, 2026
$25.34
0.7%Hi! I read Nurix Therapeutics, Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
+54.0%
Yes. Sales grew 54.0% last year.
Does it make a profit?
β314.9%
No. It lost money last year.
Does profit turn into cash?
β313.7%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 7
Weak. It passes 3 of 7 health tests.
How is the share priced?
11.0x
One share costs 11.0 times its yearly profit per share.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Nurix Therapeutics, Inc. did it, and the next one. Share prices often move a lot on those days.
Next results
January 27, 2027
Wednesday Β· in 94 days
Estimated from the same quarter last year. It will be replaced by the announced date once there is one.
See who else reports that week β| Date | Results for | Time | Source |
|---|---|---|---|
| Oct 12, 2026 | Q3 '26 | Time not announced | 8-K β |
| Jul 9, 2026 | Q2 '26 | After the market closes | 8-K β |
| Apr 8, 2026 | Q1 '26 | Before the market opens | 8-K β |
| Jan 28, 2026 | Q4 '25 | After the market closes | 8-K β |
| Oct 9, 2025 | Q3 '25 | After the market closes | 8-K β |
| Jul 9, 2025 | Q2 '25 | After the market closes | 8-K β |
| Apr 8, 2025 | Q1 '25 | After the market closes | 8-K β |
| Jan 13, 2025 | Q4 '24 | Before the market opens | 8-K β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· Nurix Therapeutics, Inc. had $84.0M of revenue in fiscal 2025, up 54.0% on the year before. Over five years, revenue changed +36.3% a year on average. Its operating margin was β340.2%, up 50.4Β pts: of every 100 in sales, about β340 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Nurix Therapeutics, Inc. lost $264M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$263M in fiscal 2025, β313.7% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
Cash, debt and the ratios that show how comfortably Nurix Therapeutics, Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $296M | $309M | $54.6M | $110M | $247M |
| Current ratio | 4.7x | 4.5x | 3.4x | 6.5x | 7.0x |
| Quick ratio | 4.7x | 4.5x | 3.4x | 6.5x | 7.0x |
| Total assets | $477M | $417M | $356M | $669M | $688M |
| Total liabilities | $134M | $113M | $155M | $142M | $149M |
| Shareholders' equity | $342M | $304M | $200M | $527M | $539M |
| Net debt (β = net cash) | β | β | β | β | β |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Nurix Therapeutics, Inc. passes 3 of 7 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β |
| F-score | β / 3 | 3 / 7 | 2 / 7 | 2 / 7 | 3 / 7 | 3 / 7 | 3 / 7 |
| Accruals ratio | β50.6% | β19.6% | β7.5% | β4.6% | β16.2% | β4.1% | β2.2% |
| Altman Z'' | β5.54 | 5.12 | 2.87 | 0.62 | β2.72 | 3.28 | 1.20 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | $31.1M | $17.8M | $29.8M | $38.6M | $77.0M | $54.5M | $84.0M |
| Research and development | $45.0M | $66.5M | $116M | $184M | $189M | $222M | $317M |
| Operating income | β$22.2M | β$65.0M | β$118M | β$184M | β$155M | β$213M | β$286M |
| Pretax income | β$21.5M | β$63.8M | β$117M | β$180M | β$144M | β$193M | β$264M |
| Income tax | $0.2M | β$20.5M | $0.1M | $0.0M | $0.0M | $0.3M | $0.8M |
| Net income | β$21.7M | β$43.2M | β$117M | β$180M | β$144M | β$194M | β$264M |
| Diluted EPS | β$6.59 | β$2.76 | β$2.73 | β$3.71 | β$2.65 | β$2.88 | β$3.05 |
| Diluted shares | 0.00B | 0.02B | 0.04B | 0.05B | 0.05B | 0.07B | 0.09B |
| Cash flow | |||||||
| Cash from operations | $0.6M | β$0.1M | β$84.4M | β$160M | β$81.4M | β$173M | β$249M |
| Capital expenditure | $1.7M | $4.6M | $5.7M | $12.2M | $8.4M | $9.3M | $14.0M |
| Free cash flow | β$1.1M | β$4.6M | β$90.0M | β$172M | β$89.8M | β$182M | β$263M |
| Depreciation and amortization | $2.4M | $2.2M | $2.8M | $5.3M | $7.5M | $9.3M | $8.7M |
| Stock-based compensation | $0.5M | $4.3M | $15.8M | $28.1M | $33.7M | $33.9M | $38.0M |
| Balance sheet | |||||||
| Cash and short-term investments | $37.7M | $281M | $296M | $309M | $54.6M | $110M | $247M |
| Current assets | $39.4M | $298M | $311M | $318M | $296M | $619M | $607M |
| Current liabilities | $16.1M | $44.5M | $66.3M | $70.7M | $87.0M | $95.9M | $86.5M |
| Property and equipment, net | $3.9M | $6.7M | $11.3M | $17.2M | $16.8M | $17.8M | $22.5M |
| Total assets | $44.0M | $396M | $477M | $417M | $356M | $669M | $688M |
| Total liabilities | $53.6M | $106M | $134M | $113M | $155M | $142M | $149M |
| Preferred stock | β | β | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | β$57.7M | $290M | $342M | $304M | $200M | $527M | $539M |
| Margins | |||||||
| Operating margin | β71.5% | β364.7% | β396.3% | β476.0% | β201.4% | β390.5% | β340.2% |
| EBITDA margin | β63.9% | β352.4% | β386.9% | β462.2% | β191.6% | β373.4% | β329.8% |
| Net margin | β69.7% | β242.7% | β393.9% | β466.9% | β187.0% | β354.9% | β314.9% |
| FCF margin | β3.4% | β26.0% | β302.6% | β445.4% | β116.6% | β333.4% | β313.7% |
| Returns | |||||||
| Return on capital employed | β79.7% | β18.5% | β28.7% | β53.1% | β57.7% | β37.1% | β47.5% |
| Return on equity | β | β37.2% | β37.1% | β55.8% | β57.1% | β53.2% | β49.6% |
| Return on assets | β49.3% | β19.6% | β26.8% | β40.4% | β37.3% | β37.8% | β39.0% |
| Return on tangible equity | β | β14.9% | β34.2% | β59.4% | β71.8% | β36.7% | β49.1% |
| Growth | |||||||
| Revenue growth | β | β42.7% | 66.9% | 29.8% | 99.3% | β29.1% | 54.0% |
| Share count change | β | 376.0% | 173.7% | 13.3% | 11.8% | 23.5% | 29.1% |
| Financial health | |||||||
| Current ratio | 2.4x | 6.7x | 4.7x | 4.5x | 3.4x | 6.5x | 7.0x |
| Quick ratio | 2.4x | 6.7x | 4.7x | 4.5x | 3.4x | 6.5x | 7.0x |
| Capital allocation | |||||||
| Capex / revenue | 5.3% | 25.5% | 19.0% | 31.7% | 10.9% | 17.0% | 16.7% |
| Stock comp / revenue | 1.6% | 24.1% | 53.1% | 72.8% | 43.7% | 62.2% | 45.2% |
| Quality scores | |||||||
| Piotroski F-score | β | 3.0 | 2.0 | 2.0 | 3.0 | 3.0 | 3.0 |
| Altman Z'' | β5.5 | 5.1 | 2.9 | 0.6 | β2.7 | 3.3 | 1.2 |
| Accruals ratio | β50.6% | β19.6% | β7.5% | β4.6% | β16.2% | β4.1% | β2.2% |
Source: SEC EDGAR XBRL filings (CIK 0001549595). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
